These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam. Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864 [TBL] [Abstract][Full Text] [Related]
8. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam. Chin NX; McElrath MJ; Neu HC Chemotherapy; 1988; 34(4):318-25. PubMed ID: 2850139 [TBL] [Abstract][Full Text] [Related]
9. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Blazquez J; Baquero MR; Canton R; Alos I; Baquero F Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123 [TBL] [Abstract][Full Text] [Related]
10. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases. Payne DJ; Cramp R; Winstanley DJ; Knowles DJ Antimicrob Agents Chemother; 1994 Apr; 38(4):767-72. PubMed ID: 8031044 [TBL] [Abstract][Full Text] [Related]
11. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae. Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705 [TBL] [Abstract][Full Text] [Related]
12. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases. Bonomo RA; Rudin SA; Shlaes DM FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111 [TBL] [Abstract][Full Text] [Related]
16. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes. Appelbaum PC; Jacobs MR; Spangler SK; Yamabe S Antimicrob Agents Chemother; 1986 Nov; 30(5):789-91. PubMed ID: 3026241 [TBL] [Abstract][Full Text] [Related]
17. Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam. Moosdeen F; Williams JD; Yamabe S Antimicrob Agents Chemother; 1988 Jun; 32(6):925-7. PubMed ID: 2843088 [TBL] [Abstract][Full Text] [Related]
18. Penicillanic acid sulfone: nature of irreversible inactivation of RTEM beta-lactamase from Escherichia coli. Brenner DG; Knowles JR Biochemistry; 1984 Nov; 23(24):5833-9. PubMed ID: 6098299 [TBL] [Abstract][Full Text] [Related]
19. Protection of piperacillin and ticarcillin from beta-lactamase hydrolysis by tazobactam (YTR-830) and clavulanic acid. Diver JM; Thornber D; Wise R J Antimicrob Chemother; 1989 Jul; 24(1):89-92. PubMed ID: 2550415 [No Abstract] [Full Text] [Related]
20. Synthesis and beta-lactamase inhibitory activity of 6-[(1-heteroarylthioethyl-1,2,3-triazol-4-yl)-methylene]penam sulfones. Im C; Maiti SN; Micetich RG; Daneshtalab M; Atchison K; Phillips OA; Kunugita C J Antibiot (Tokyo); 1994 Sep; 47(9):1030-40. PubMed ID: 7928691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]